SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amid speculation that Panasonic's new EV battery tech could be linked to them and Tesla, sparking high trading volume. The community is buzzing about a potential partnership and the implications for solid-state battery technology, while some debate the impact of insider selling. Overall, sentiment appears bullish, with many anticipating significant upside.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following news of a significant partnership with Nvidia, including a substantial investment, which has ignited discussions about its implications for the competitive landscape in AI and data centers. Community members are weighing the potential benefits for Intel's turnaround and its foundry business, while also considering potential challenges and market dynamics within the semiconductor sector.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending due to its rebranding as Solmate and a $300 million private placement to establish a Solana digital asset treasury, sparking significant community discussion around its potential and comparisons to similar crypto treasury plays. The stock's volatile price action, including multiple trading halts, has traders debating its short-term direction and potential for further gains or sharp declines. Community members are actively discussing price targets, short squeezes, and the influence of large investors.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending amidst a significant price drop, with the community debating whether it's an oversold opportunity or a value trap. Recent news of increased competition and concerns about slowing growth are driving the negative sentiment, while long-term bulls cite strong fundamentals and potential for a rebound.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as the community discusses its potential shift toward AI and high-performance computing, sparked by recent CEO comments. Traders are closely watching key resistance levels, with many viewing the stock as undervalued compared to its peers in the mining sector and anticipating a possible short squeeze. Bullish sentiment is fueled by high trading volume and potential for significant upside if the company successfully executes its new strategy.

LimeWire is reshaping the creator economy, one step at a time.  The beloved platform that helped millions of users in the early 2000’s to discover their favorite music, is back - to once again reinvent how fans and artists share content and interact with each other.  LimeWire is a platform for content creators, artists and brands to create membership-based communities. Creators can build recurring revenue streams by offering fans exclusive access to their community and journey as an artist. Through blockchain technology, LimeWire makes exclusive content and assets ownable and tradeable, allowing fans to not only consume content but also to directly participate in the success of the creators they support.  The LimeWire token is an ERC-20 utility token deeply embedded into the LimeWire ecosystem, designed to provide a series of perks and benefits to holders as well as to enhance the user experience across the LimeWire platform, such as monthly token rewards, access to in person events and voting rights.   In mid-2022, LimeWire successfully closed a $10.4M strategic & private pre-sale of the LimeWire Token with a long list of strong backers including Kraken Ventures, Crypto.com Capital, GSR and Arrington Capital.

LimeWire

LimeWire ($LMWR.X) is trending as community members highlight recent news and speculate on potential exchange listings, viewing it as an AI play with significant growth potential. Despite some concerns about tokenomics, there's excitement around its low market cap, brand recognition and upcoming features, especially the AI video creator. The nostalgic appeal of the LimeWire name combined with its reinvention as an AI studio is also fueling interest.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors assess the impact of factors like insider buying, potential union actions, and the termination of a plan to acquire Estafeta. Community members are weighing positive earnings sentiment against concerns about union labor costs and overall financial health. Some traders are considering UPS for its dividend yield and potential long-term value, while others are wary of near-term headwinds.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending due to a mixed market reaction to its latest earnings report; while the company beat expectations, cautious guidance is fueling uncertainty. The community is debating whether cost-cutting is sustainable and how new tariffs will impact future profitability. Some investors are concerned about soft shipping demand and are looking for more clarity on the company's long-term strategy.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending amid analyst upgrades and anticipation surrounding potential interest rate cuts, which are seen as a tailwind for the fintech company. The community is actively discussing whether the stock will break through resistance levels and reach new all-time highs, or if profit-taking will lead to a pullback. Broader discussions include SOFI's potential inclusion in the S&P 500 and comparisons to competitors.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is gaining attention, with community members discussing its potential for growth and comparing it to other meme coins like Dogecoin. Recent articles highlight positive price predictions and potential breakout phases, generating excitement around possible rallies. The community is also closely watching for news related to potential ETFs, which could further fuel interest in PENGU.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +5.75% and +3.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates

Rigel (RIGL) delivered earnings and revenue surprises of +66.50% and +28.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nektar Gears Up to Report Q2 Earnings: What's in the Cards?

NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street analysts sharply upgraded their outlook on Nektar Therapeutics on Wednesday following positive topline results from the company’s Phase 2b REZOLVE-AD trial of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.Nektar Therapeutics’ stock closed Wednesday up 19.1% at $29.12 and added another 1.1% after hours to $29.43.Jefferies lifted its price target from $2 to $69, citing improved confidence in rezpegaldesleukin’s efficacy and safety in what it described as an “enormous disease space.”&nbsp;The firm maintained a ‘Buy’ rating.Additionally, BTIG raised its target to $100 from $60, calling the stock a “pound the table BUY” and noting that all three dose arms achieved statistical significance across primary and secondary endpoints at 16 weeks.&nbsp;BTIG analysts said the “robust” data support rezpegaldesleukin’s status as a novel mechanism of action with&nbsp;the potential to outperform current therapies.Meanwhile, H.C. Wainwright was the most bullish, increasing its target from $6.50 to $120 and calling the results “paradigm-shifting.”&nbsp;The firm said rezpeg’s highly differentiated profile could reshape the atopic dermatitis treatment landscape and noted further improvement may come in the 36-week maintenance data expected in Q1 2026.Nektar said its primary 16-week induction data&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nektar-therapeutics-announces-positive-data-from-eczema-drug-in-mid-stage-trial/chm40c0RR3i">met its primary endpoint</a>, with a statistically significant improvement in Eczema Area and Severity Index (EASI) in all dose arms versus placebo.&nbsp;The company also met its secondary endpoints, which include EASI-75, EASI-50, BSA score, vIGA-AD 0/1, Itch NRS, and EASI-90 at the highest dose.&nbsp;Safety was consistent with previous data, and&nbsp;blood biomarker data showed strong on-target, dose-dependent activity.The results will be shared at a medical conference later in 2025. The company expects to report Phase 2b data for rezpeg in alopecia areata in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said that Nektar could touch $100 as early as tomorrow.&nbsp;<stembedurl>https://stocktwits.com/LFG2030/message/619030106</stembedurl>Another speculated that, barring an immediate equity offering, the stock might reach $40 in the next session.<stembedurl>https://stocktwits.com/Majlo/message/619029852</stembedurl>Others remained cautious, noting&nbsp;that dilutive financings often follow such rallies.&nbsp;One user said an offering was likely “incoming,” potentially in the $15 range.<stembedurl>https://stocktwits.com/BIGPHILLY/message/619028491</stembedurl>Still, some bulls pushed back, dismissing near-term offering concerns as "bear hopium" and predicting a move to $49 to fill the gap, with all-time highs (ATH) as the next target.<stembedurl>https://stocktwits.com/Da_Closer/message/619027710</stembedurl>Nektar’s stock has doubled its value so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis. 

Equity

NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.nektar.com/news-releases/news-release-details/rezolve-ad-phase-2b-study-rezpegaldesleukin-meets-primary-and">announced</a> that its mid-stage study evaluating Rezpegaldesleukin in atopic dermatitis demonstrated improvement in area affected and severity.The global Phase 2b study is being conducted in 393 patients with moderate-to-severe atopic dermatitis. The company announced that, at week 16, patients who received Rezpegaldesleukin showed improvement in eczema area and severity score from baseline, as compared to placebo, using a widely used index.The trial also demonstrated that Rezpegaldesleukin reduced disease severity by as much as 90% or more with higher doses of the drug.Atopic dermatitis is the most common type of eczema, affecting approximately 30 million people in the U.S., according to Nektar. It is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inﬂammation.Rezpegaldesleukin is an investigational therapy that may address the underlying immune system imbalance in people with many autoimmune and inflammatory conditions.It targets the interleukin-2 receptor complex in the body to stimulate the proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, Rezpegaldesleukin aims to restore the immune system's balance.The company is now looking forward to reporting results from its trial of Rezpegaldesleukin in alopecia areata, an autoimmune disease that causes hair loss, in the fourth quarter of this year.Following the update from the company, H.C. Wainwright raised the firm's price target on Nektar to $120 from $6.50 while keeping a ‘Buy’ rating on the shares.On Stocktwits, retail sentiment around Nektar jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_04_09_PM_png_6458c1b61c.webp" alt="NKTR's Sentiment Meter and Message Volume as of 12 p.m. ET on June 24, 2025 | Source: Stocktwits" width="628" height="66"><figcaption>NKTR's Sentiment Meter and Message Volume as of 12 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the user to jump as much as 150% later today.<stembedurl>https://stocktwits.com/US_Bull/message/618826543</stembedurl><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> is up by 66% this year and by about 32% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-tells-congress-fed-can-wait-on-rate-cuts-despite-pressure-from-trump/chm4hMMRR3h">Jerome Powell Tells Congress Fed Is ‘Well Positioned To Wait’ On Rate Cuts Despite Mounting Pressure From Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further

Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16.

Nektar Therapeutics shares jumped 35.3% in&nbsp;extended trading Monday after the company said it&nbsp;would release topline results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for atopic dermatitis on Tuesday.The stock closed Monday’s regular session up 12.1% at $9.54.The experimental treatment is called NKTR-358 or REZPEG. It's a first-in-class regulatory T-cell (Treg) stimulator in development for autoimmune and inflammatory skin diseases.Nektar will hold an investor webcast at 8:15 a.m. ET on June 24 to discuss the 16-week induction data from the global trial.The stock reaction follows CEO Howard Robin's remarks in May that the company was on track to deliver trial results in June, positioning rezpegaldesleukin to emerge as an “important novel mechanism” to treat patients with chronic autoimmune disorders.The company also reiterated that topline data from a separate Phase 2 trial in alopecia areata are expected by December.In its most recent earnings report, Nektar posted a Q1 adjusted loss of&nbsp;$0.22 per share, wider than the consensus estimate of&nbsp;$0.19 loss per share. Revenue came in at $10.5 million, below analysts' expectations of $15.36 million.Robin also said Nektar is advancing other pipeline assets, including NKTR-0165 for multiple sclerosis and ulcerative colitis and a bispecific antibody candidate, NKTR-0166, both targeting the TNFR2 receptor.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,600% surge in 24-hour message volume.One user expects shares of Nektar to climb to the $14–$15 range overnight.&nbsp;<stembedurl>https://stocktwits.com/RealBobbyAxelrod/message/618755635</stembedurl>Another user noted the strong after-hours move likely reflected optimism, but expressed uncertainty about holding the position, saying they were tempted to take some profits.<stembedurl>https://stocktwits.com/Patrick2343/message/618743686</stembedurl>The stock has declined 33.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, a biopharmaceutical company located on 3rd Street, in the Mission Bay District of San Francisco, California, October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away

Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$58.68
Prev Close	$51.07
Open	$55.61
Dividend Yield	0.00%
50-Day Moving Average	$29.49
Beta	1.91
Avg. Volume	653,115.57
PE Ratio	-5.86

52-Week High	$52.75
52-Week Low	$6.48
Market Capitalization	$971.28M
EPS (Annual)	-$8.68
Price to Book	-26.28
Revenue Per Employee	$1.61M
Enterprise Value/EBITDA	N/A

NKTR
Nektar Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NKTR News

NKTR Nektar Therapeutics